Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant Stenotrophomonas maltophilia. 2020

M Biagi, and D Lamm, and K Meyer, and A Vialichka, and M Jurkovic, and S Patel, and R E Mendes, and Z P Bulman, and E Wenzler
College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA.

The intrinsic L1 metallo- and L2 serine-β-lactamases in Stenotrophomonas maltophilia make it naturally multidrug resistant and difficult to treat. There is a need to identify novel treatment strategies for this pathogen, especially against isolates resistant to first-line agents. Aztreonam in combination with avibactam has demonstrated potential, although data on other aztreonam-β-lactamase inhibitor (BLI) combinations are lacking. Additionally, molecular mechanisms for reduced susceptibility to these combinations have not been explored. The objectives of this study were to evaluate and compare the in vitro activities and to understand the mechanisms of resistance to aztreonam in combination with avibactam, clavulanate, relebactam, and vaborbactam against S. maltophilia A panel of 47 clinical S. maltophilia strains nonsusceptible to levofloxacin and/or trimethoprim-sulfamethoxazole were tested against each aztreonam-BLI combination via broth microdilution, and 6 isolates were then evaluated in time-kill analyses. Three isolates with various aztreonam-BLI MICs were subjected to whole-genome sequencing and quantitative reverse transcriptase PCR. Avibactam restored aztreonam susceptibility in 98% of aztreonam-resistant isolates, compared to 61, 71, and 15% with clavulanate, relebactam, and vaborbactam, respectively. The addition of avibactam to aztreonam resulted in a ≥2-log10-CFU/ml decrease at 24 h versus aztreonam alone against 5/6 isolates compared to 1/6 with clavulanate, 4/6 with relebactam, and 2/6 with vaborbactam. Molecular analyses revealed that decreased susceptibility to aztreonam-avibactam was associated with increased expression of genes encoding L1 and L2, as well as the efflux pump (smeABC). Aztreonam-avibactam is the most promising BLI-combination against multidrug-resistant S. maltophilia Decreased susceptibility may be due to the combination of overexpressed β-lactamases and efflux pumps. Further studies evaluating this combination against S. maltophilia are warranted.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D001897 Boronic Acids Inorganic or organic compounds that contain the basic structure RB(OH)2. Boronic Acid,Acid, Boronic,Acids, Boronic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D001398 Aztreonam A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms. Az-threonam,Azactam,Azthreonam,SQ-26,776,Urobactam,Az threonam,SQ 26,776,SQ26,776
D012756 Sheep Any of the ruminant mammals with curved horns in the genus Ovis, family Bovidae. They possess lachrymal grooves and interdigital glands, which are absent in GOATS. Ovis,Sheep, Dall,Dall Sheep,Ovis dalli
D016905 Gram-Negative Bacterial Infections Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method. Bacterial Infections, Gram-Negative,Infections, Gram-Negative Bacterial,Bacterial Infection, Gram-Negative,Gram Negative Bacterial Infections,Gram-Negative Bacterial Infection,Infection, Gram-Negative Bacterial
D053961 Azabicyclo Compounds Bicyclic bridged compounds that contain a nitrogen which has three bonds. The nomenclature indicates the number of atoms in each path around the rings, such as [2.2.2] for three equal length paths. Some members are TROPANES and BETA LACTAMS. Azabicyclo(1.1.0)Butanes,Azabicyclo(2.2.2)Octanes,Azabicyclo(3.3.1)Nonanes,Azabicyclo(4.3.0)Nonanes,Azabicyclo(5.2.2)Undecanes
D019818 Clavulanic Acid A beta-lactam antibiotic produced by the actinobacterium Streptomyces clavuligerus. It is a suicide inhibitor of bacterial beta-lactamase enzymes. Administered alone, it has only weak antibacterial activity against most organisms, but given in combination with other beta-lactam antibiotics it prevents antibiotic inactivation by microbial lactamase. Clavulanate,BRL-14151,Clavulanate Potassium,Clavulanic Acid, Monopotassium Salt,Clavulanic Acid, Monosodium Salt,MM-14151,Potassium Clavulanate,Sodium Clavulanate,BRL 14151,BRL14151,Clavulanate, Potassium,Clavulanate, Sodium,MM 14151,MM14151,Potassium, Clavulanate

Related Publications

M Biagi, and D Lamm, and K Meyer, and A Vialichka, and M Jurkovic, and S Patel, and R E Mendes, and Z P Bulman, and E Wenzler
August 2022, Microbial drug resistance (Larchmont, N.Y.),
M Biagi, and D Lamm, and K Meyer, and A Vialichka, and M Jurkovic, and S Patel, and R E Mendes, and Z P Bulman, and E Wenzler
August 2021, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
M Biagi, and D Lamm, and K Meyer, and A Vialichka, and M Jurkovic, and S Patel, and R E Mendes, and Z P Bulman, and E Wenzler
June 2023, Journal of infection in developing countries,
M Biagi, and D Lamm, and K Meyer, and A Vialichka, and M Jurkovic, and S Patel, and R E Mendes, and Z P Bulman, and E Wenzler
January 2024, PloS one,
M Biagi, and D Lamm, and K Meyer, and A Vialichka, and M Jurkovic, and S Patel, and R E Mendes, and Z P Bulman, and E Wenzler
February 2025, The Journal of antibiotics,
M Biagi, and D Lamm, and K Meyer, and A Vialichka, and M Jurkovic, and S Patel, and R E Mendes, and Z P Bulman, and E Wenzler
October 2025, The Journal of antimicrobial chemotherapy,
M Biagi, and D Lamm, and K Meyer, and A Vialichka, and M Jurkovic, and S Patel, and R E Mendes, and Z P Bulman, and E Wenzler
September 2014, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
M Biagi, and D Lamm, and K Meyer, and A Vialichka, and M Jurkovic, and S Patel, and R E Mendes, and Z P Bulman, and E Wenzler
September 2023, Antibiotics (Basel, Switzerland),
M Biagi, and D Lamm, and K Meyer, and A Vialichka, and M Jurkovic, and S Patel, and R E Mendes, and Z P Bulman, and E Wenzler
November 2023, Journal of chemotherapy (Florence, Italy),
M Biagi, and D Lamm, and K Meyer, and A Vialichka, and M Jurkovic, and S Patel, and R E Mendes, and Z P Bulman, and E Wenzler
February 2004, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy,
Copied contents to your clipboard!